An evaluation and an examination of the optimization of the cancer immunotherapy for advanced non-small cell lung cancer
Not Applicable
- Conditions
- Patients with advanced non-small cell lung cancer who are going to receive a therapy with immune checkpoint Inhibitors
- Registration Number
- JPRN-UMIN000031127
- Lead Sponsor
- Tohoku Medical and Pharmaceutical University,Tohoku Medical and Pharmaceutical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients having an overlap cancer with activity Patients that an doctor judged to be inappropriate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We examine the immunoreaction with the immune checkpoint inhibitor and the association of the clinical response.
- Secondary Outcome Measures
Name Time Method